Gemphire Therapeutics Inc. 4
4 · Gemphire Therapeutics Inc. · Filed Aug 12, 2016
Insider Transaction Report
Form 4
Bisgaier Charles PhD
DirectorChair & Chief Scientific Off.10% Owner
Transactions
- Conversion
Common Stock
2016-08-10+59,561→ 59,561 total(indirect: By Trust) - Conversion
Common Stock
2016-08-10$6.71/sh+16,144$108,260→ 82,220 total(indirect: By Trust) - Conversion
Common Stock
2016-08-10$6.71/sh+19,228$128,941→ 19,228 total(indirect: By LLC) - Purchase
Common Stock
2016-08-10$10.00/sh+51,750$517,500→ 1,244,440 total - Conversion
Series A Convertible Preferred Stock
2016-08-10−59,561→ 0 total(indirect: By Trust)→ Common Stock (59,561 underlying) - Conversion
8% Convertible Subordinated Promissory Notes
2016-08-10→ 0 total(indirect: By Trust)Exercise: $6.71→ Common Stock (16,144 underlying) - Conversion
8% Convertible Subordinated Promissory Notes
2016-08-10→ 0 total(indirect: By LLC)Exercise: $6.71→ Common Stock (19,228 underlying) - Other
Common Stock
2016-08-10$6.71/sh+6,515$43,689→ 66,076 total(indirect: By Trust)
Footnotes (5)
- [F1]The Series A Convertible Preferred Stock converted into shares of common stock, par value $0.001 per share (the "Common Stock"), of Gemphire Therapeutics Inc. (the "Company") on a one-for-one basis immediately prior to the closing of the Company's initial public offering and had no expiration date.
- [F2]These shares are indirectly owned by the reporting person as trustee of The Charles L. Bisgaier Trust.
- [F3]Represents shares of Common Stock issued for payment of accrued dividends on the Series A Convertible Preferred Stock.
- [F4]The notes were issued in the original principal amount of $100,000. The outstanding principal and $8,263 of accrued interest on the notes automatically converted into shares of Common Stock immediately prior to the closing of the Company's initial public offering.
- [F5]The notes were issued in the original principal amount of $125,000. The outstanding principal and $3,945 of accrued interest on the notes automatically converted into shares of Common Stock immediately prior to the closing of the Company's initial public offering.